Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
While the therapy still showed a favourable safety profile and Novo plans further higher-dose trials, todays outcome underscores how small differences in efficacy can have outsized implications for commercial positioning and investor sentiment in weight-loss drug development
8 mg per week Resulted in substantial body weight decreases, suggesting it may offer an optimal balance between efficacy and tolerability
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (PubMed record)
95% CI 0.410.95)
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Turri Quarenghi, R
Its a way to approach weight care with confidence, knowing youre backed by a plan that fits your unique needs
US$ 29.47
US$ 24.73
US$ 25.62
US$ 23.84
US$ 25.28
US$ 23.03
